MDK-703
Immuno-oncology (T-cell modulation)
PreclinicalActive
Key Facts
About Medikine
Medikine is a private, preclinical-stage biotech developing a new class of cytokine mimetic drugs called PEPTIKINES. Its proprietary discovery platform enables the creation of small, structurally unrelated peptide agonists that can be engineered for optimized pharmacokinetics, reduced immunogenicity, and improved therapeutic windows compared to natural cytokines. The company's lead candidate, MDK-703, is an IL-7 mimetic aimed at immuno-oncology, with a pipeline targeting oncology, autoimmune disorders, and infectious diseases. Backed by experienced founders and venture capital, Medikine seeks to translate its validated platform technology into transformative therapies.
View full company profile